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Reduced insight has been reported in a majority of patients
with a psychotic disorder. Most studies have focused on
associations with neurocognition, neglecting relations
with social cognition. Two hundred seventy patients with
nonaffective psychosis participated in this study, which
was part of the GROUP (Genetic Risk and OUtcome of
Psychosis)-project. Linear regression analyses were per-
formed to investigate the predictive value of composite
measures of neurocognition, social cognition, and clinical
symptoms. The moderating effect of phase of illness was
also investigated. Insight was measured with a composite
measure, based on the insight item on the Positive AndNeg-
ative Syndrome Scale (PANSS) and the Birchwood Insight
Scale (BIS). Insight on the BIS and the PANSS correlated
significantly (r 5 .406). All independent variables corre-
lated with the insight composite measure. The additional
effect of social cognition and clinical symptoms were
both significant. Phase of illness was a moderating vari-
able: In patients with recent-onset psychosis (ROP),
none of the independent variables explained variance. In
patients with multiple episode or chronic psychosis, both
social cognition and clinical symptoms had additional
effects and explained insight, along with neurocognition,
together explaining 20% of the variance. These findings in-
dicate that multiple factors are associated with insight in
psychosis. Specifically, associations of insight with social
cognitive and clinical symptom measures were observed,
over and above a contribution of neurocognition. This sup-
ports theories that imply a role for deficient emotion rec-
ognition and mentalizing in reduced insight. Further studies




Reduced insight (or unawareness of illness) has been
reported in a majority of patients with a nonaffective psy-
chotic disorder.1 Insight can be studied as a set of descrip-
tive beliefs and as a personal narrative.2 Most studies
investigating the neurocognitive correlates of insight
treat the concept as a set of descriptive beliefs, mostly
to formalize the concept of insight and thus enabling
the subject for quantitative research. Even though study-
ing insight as a personal narrative is of great importance
to understand the individual differences with regard to
insight, this approach is of a highly subjective nature,
making it very hard to study the concept in a quantitative
manner. In the current study, consistent with previous
studies that investigated insight in psychosis and cogni-
tive function, we focused on insight as a set of descriptive
beliefs for which 3 distinct dimensions have been pro-
posed: (1) the recognition that one has a mental illness,
(2) the recognition of the need for treatment, and (3) the
ability to relabel unusual mental events (delusions and
hallucinations) as pathological.3 The concept of insight
is clinically relevant because poor insight is associated
with psychosocial dysfunction and poorer treatment ad-
herence, in addition to an increase in the number of rehos-
pitalizations.4 Therefore, investigating which factors are
specifically related to poor insight is of crucial impor-
tance for understanding psychotic disorders and for fur-
ther development of treatment strategies.
Over the past decades, a considerable number of stud-
ies have investigated the association between neurocog-
nition and insight. A meta-analysis of these studies
found that, although there was a significant relationship,
the predictive value of neurocognition was rather
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modest.5 Furthermore, in schizophrenia, all neurocogni-
tive domains (ie, reasoning and problem solving, verbal
learning, and memory) were found to predict reduced in-
sight to a similar degree. Thus, employing a composite
measure of several neurocognitive domains6 may be ad-
equate and may enhance reliability. It is also possible that
other neuropsychological aspects are associated with in-
sight. Indeed, in recent years, there is increasing interest
in the concept of social cognitive impairments in psycho-
sis. Social cognition has been referred to as ‘‘the ability to
construct representations of the relations between oneself
and others and to use those representations flexibly to
guide social behavior.’’7 Studies of social cognition in
psychosis have mainly focused on emotion perception
and theory-of-mind processing.8 The combination of im-
paired social cognition and poor insight has been
reported in other populations with brain abnormali-
ties.9,10 In addition, some studies have reported a relation-
ship between social cognition and insight in psychosis as
well,11,12 whereas others have not.13 When investigating
factors associated with insight, it should be taken into ac-
count that social cognition and neurocognition are par-
tially overlapping concepts.14 However, most of the
studies to date have investigated whether social cognition
or neurocognition is more related to insight, not whether
1 of these factors is of additional value in explaining
insight.
A third group of factors that have been found to be
related to insight are clinical symptoms.15 Relationships
with positive symptoms, negative symptoms, and disor-
ganization have been found.15 Some researchers claim
that symptoms have more predictive value on insight
as compared with neurocognition,6,16,17,18 whereas others
suggest that these factors may not be mutually exclu-
sive.19 As with social cognition, no studies have been
done to determine whether clinical symptoms really
have additional predictive value.
Insight is a complex and multi-dimensional concept
and may be related to neuropsychological aspects as
well as severity of psychopathology. Thereby, insight
may be influenced by so-called ‘‘trait’’ and ‘‘state’’ fea-
tures of psychosis, in which neurocognition has tradition-
ally been associated with the former, and positive
symptoms with the latter, whereas the influence of social
cognition is not unequivocal.20–23 The phase of illness
could be differentially related to various insight-related
factors. Tranulis et al 24 studied insight in patients in
recent-onset psychosis (ROP) and found that self-report
and interview-based insight scales were not correlated
with one another in this population, which was attributed
to the nature of their relatively unstable and evolving
period.
The current study was part of the large-scale Genetic
Risk and OUtcome of Psychosis (GROUP) study. Data
were obtained from a sample of relatively young patients,
including those with ROP. A neuropsychological assess-
ment was administered in line with the cognitive dimen-
sions used in Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS),25 in-
cluding social cognition. Composite measures were cre-
ated for insight, neurocognition, social cognition, and
clinical symptoms. The insight composite measure was
based on an interview and a self-report questionnaire.
It was expected that insight would be better explained
by a model that included neurocognition as well as social
cognition, as compared to a model that only encom-
passed neurocognition.19,27 Similarly, clinical symptoms,
social cognition, and neurocognition were expected to
predict insight better, particularly when as compared




Two hundred seventy patients with psychotic disorders
were included in this study. This was a subsample of
the patient population participating in the GROUP pro-
ject. Two out of 4 centers participated in the insight pro-
ject (Amsterdam and Utrecht). The GROUP project is
a large-scale multi-center study that investigates the vul-
nerability and protective factors for (1) the development
of a psychotic disorder and (2) the variation in the course
of illness. Diagnoses were confirmed using the Compre-
hensive Assessment of Symptoms and History.27 The
procedure of recruitment, criteria of inclusion and exclu-
sion, informed consent, assessment instruments, ap-
proval by the accredited Medical Ethics Review
Committee, and population characteristics have been de-
scribed in a previous report on the GROUP study (N.
Korver, P. J. Quee, H. B. M. Boos, C. J. P. Simons,
GROUP, unpublished data, 2010).
Eligible patients had to fulfill the following criteria: (1)
age: between 18 and 50 (extremes included), (2) meeting
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria for a nonaffective psy-
chotic disorder (schizophrenia, schizophreniform disor-
der, schizoaffective disorder, delusional disorder,
psychotic disorder NOS), (3) fluent in Dutch, (4) able
and willing to give written informed consent, and (5)
the willingness of at least 1 family member to participate
in the project.
Table 1 shows the demographic and clinical data for
the patient group. Educational degree was adapted
from Verhage.29 Global Assessment of Functioning
(GAF) scores, adapted from the DSM-IV, were obtained
to measure global symptoms and disability.30 Level of in-
telligence was estimated with the Wechsler Adult Intelli-
gence Scale-III (WAIS-III) short form.29,32 ROP was
defined as follows: 1 psychotic episode in the year prior
to the assessment. The other patients had an illness
P. J. Quee et al.
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duration of longer than 1 year, or had experienced mul-
tiple psychotic episodes and were therefore characterized
as having ‘‘multiple episode or chronic psychosis’’
(MECP).
Assessment of Insight
Insight was assessed by means of a semi-structured inter-
view, the Positive And Negative Syndrome Scale
(PANSS),32 as well as a self-report scale, the Birchwood
Insight Scale (BIS).26 The PANSS provides a single
item on insight (G12), based on the patient’s ability to de-
scribe and acknowledge symptoms and their psychiatric
disorder, the ability to recognize the necessity of treatment,
and the ability to describe future plans. Researchers were
not always blind to the other outcome measures (eg, cog-
nitive task performance): It has been suggested that this
did not influence their knowledge of the patients’ cognitive
functioning while judging insight. The BIS is a short ques-
tionnaire that consists of 8 questions addressing the 3 com-
ponents of insight (Need for Treatment, Awareness of
Illness, and Relabeling of Symptoms). Each of these com-
ponents is rated on a scale of 0–4: a higher score implies
better insight. A composite measure was created, based on
both the patients’ z-score on the BIS and PANSS, with the
latter being negatively recoded. Higher scores on the com-
posite measure indicated better insight. The procedure for
translation of all raw scores into z-scores is described in the
‘‘Statistical Analysis’’ section.
Neurocognition
All patients were assessed with a neurocognitive task bat-
tery containing the following 6 tasks (intended neurocog-
nitive domains of focus are placed between brackets):
WAIS-III Digit Symbol Coding (processing speed), Con-
tinuous Performance Test-HQ (attention/vigilance),31
Word Learning Task (verbal learning and memory),33
WAIS-III Arithmetic (working memory), WAIS-III
Block Design (reasoning and problem solving), Response
Set Shifting (set-shifting), WAIS-III Information (verbal
comprehension),28 and educational degree.29 z-Scores
were calculated for each domain, with d’ indicating a final
score for attention/vigilance.34 For verbal learning &
memory, the final z-score was based on the mean value
of 2 distinct z-scores: immediate recall and delayed recall.
For set-shifting, the z-score was based on the decrement
in accuracy performance from an imitation response con-
dition to reversal response, using the Response Set Shift-
ing task, a modified version of the Competing Programs
Task.35 Due to its high correlations with neurocognition,
a z-score for educational degree was also created.36
A final composite measure of neurocognition was based
on the mean of the z-scores from the 7 outcome variables,
while allowing for 4 missing values.
Social Cognition
In addition to the neurocognitive battery, patients were
assessed with 2 social cognitive tasks, concerning emotion
perception and theory of mind. The degraded facial affect
recognition task was used as a measure of emotion per-
ception.37 Sixty-four trials were presented, consisting of
16 face presentations in each of 4 conditions: angry,
happy, fearful, and neutral. Patients were asked to label
each expression with the appropriate emotion. Theory of
mind (or mentalizing) was assessed using the Hinting
Task.38 This task tests the ability of subjects to infer
the real intentions behind indirect speech utterances.
The task comprises 10 short passages presenting an inter-
action between 2 characters. All passages end with 1 of
the characters dropping a hint. For instance, following
a long and exhausting journey, Peter enters Ann’s office.
Ann immediately starts to update him on a number of
business developments. Peter interrupts Ann by saying
‘‘Gosh, that really was a long, exhausting journey.’’
The participant is asked to describe what he thinks Peter
is implying with this comment. A composite measure for
social cognition was based on the z-score on both tasks,
allowing for 1 missing value.




Age (years) 27.7 6.5
Gender (N), male/female 222/48
Educational degree (score), Verhage 4.2 2.1
Ethnicity (N), Dutch/other/unknown 209/52/9
WAIS-III estimated IQ (short form)28 95.1 16.1
Duration of illness (years) 4.7 4.6
Psychotic episodes (number) 1.7 1.1
Age of onset psychosis (years) 22.5 6.2
Diagnostic (N)
Schizophrenia, paranoid type 143
Schizoaffective disorder 39




Phase of illness (N)
Recent onset psychosis 57
Multiepisode or chronic psychosis 210
Unknown 3
Hospitalizations (number) 2.2 2.1








Interview based (G12) 2.3 1.4
Self-report (IS) 8.8 2.8
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In the GROUP project, current symptom severity was
measured with the PANSS, which consists of 30 items.
Each item is scored on a scale ranging from 1 (absent)
to 7 (extreme), with item rating incorporating the behav-
ioral effect of symptoms as well as their severity. Origi-
nally, 3 domains or factors were described for the
PANSS. Later, a 5-factor structure was developed.39 A
more universally used method is that of remission, for
which a number of items (measuring positive, negative,
or disorganization symptoms) on the PANSS have
been selected that also appear in other symptom rating
scales. For remission, a score of 3 or lower for a period
of 6 months on the following items is required (PANSS
items are placed between brackets): delusions (P1), un-
usual thought content (G9), hallucinatory behavior
(P3), conceptual disorganization (P2), mannerisms/pos-
turing (G5), blunted affect (N1), social withdrawal
(N4), and lack of spontaneity (N6).40 Because the current
study did not emphasize symptom dimensions but rather
the concept of clinical symptoms in relation to insight, we
decided to calculate the mean (cross-sectional) score of
the z-transformed remission items, allowing for 3 missing
values.
Statistical Analysis
Subject scores exceeding 2 SD from the mean patient
group score were replaced by the recalculated mean
group score 62 SD. All variables measuring insight
(PANSS G12 and BIS), neurocognition, social cognition,
and clinical symptoms (see ‘‘Assessment of Insight, Neu-
rocognition, Social Cognition, and Clinical Symptoms’’
sections) were checked for normal distribution of resid-
uals from regression analysis41 and transformed into
z-scores using the mean and SD of the patient group.
Otherwise, test scores were transformed to approximate
normality by logarithmic, square root, or reciprocal
transformations. Higher scores on the neurocognitive
and social cognitive domains indicated better perfor-
mance, whereas higher scores on the clinical symptom di-
mension indicated more severe symptomatology. Missing
values were replaced by the average z-score, which is zero
(BIS and PANSS G12: both 11 cases; neurocognition and
social cognition: both 6 cases; and clinical symptoms: 11
cases).
First, bivariate correlation analyses were performed to
separately investigate relations between insight and neu-
rocognition, social cognition, and clinical symptoms.
Second, we investigated the additional explained vari-
ance using multiple regression analysis. Neurocognition,
social cognition, and clinical symptoms were entered
blockwise. This enabled us to investigate the explained
variance of each factor in 1 model, as well as the addi-
tional explained variance of social cognition as well as
the additional explained variance of clinical symptoms.
Age, gender, and phase of illness (recent-onset/multiple
episode or chronic psychosis) were entered as covariates
into the first block.
Next, we investigated the moderating role of phase of
illness. This was done by repeating the first regression
analyses, but with the addition of 3 interaction terms: neu-
rocognition3 recent onset yes/no, social cognition3 recent
onset yes/no, and clinical variables x recent onset yes/no.
Finally, 2 separate regression analyses were performed
for ROP and MECP with only those predictors that
showed a significant interaction with recent onset yes/
no in the previous regression analysis. All analyses
were performed with 1-tailed hypothesis testing with
a = .05. Statistical analyses were performed using SPSS
16.0. For descriptive purposes, correlations between all
variables are displayed in supplementary table S1.
Results
Self-Reported Insight and Interview-Based Insight
Self-reported insight was significantly correlated with in-
terview-based insight (r = .406, P < 0.001). Score on the
PANSS and BIS correlated significantly with the com-
posite measure of insight (r = .837, P < 0.001; r =
.846, P < 0.001, respectively), as with the BIS subscales
Relabeling of Symptoms (r = .615, P< 0.001), Awareness
of Illness (r = .672, P <0.001), and Need for Treatment
(r = .682, P < 0.001). On the raw PANSS G12 scores,
43.1% of the patients (n = 132) had no impairment of
insight, 17.0% had ‘‘minimal’’ impairment, 15.7% had
‘‘mild impairment’’ (n = 48), 11.8% had ‘‘moderate im-
pairment’’ (n = 35), 5.1% had ‘‘moderately severe impair-
ment’’ (n = 15), 4.1% had ‘‘severe impairment’’ (n = 12),
and 0.7% had ‘‘extreme impairment’’ (n = 2). On the raw
BIS scores, 50.7% had a score in the ‘‘no-mild impair-
ment’’ range (9.1–12; n = 103), 30.3% had a score in
the ‘‘mild-moderate impairment’’ range (6.1–9; n = 93),
14.1% had a score in the ‘‘moderate-severe impairment’’
range (3.1–6; n = 43), and 4.9% had a score in the ‘‘severe-
extreme impairment’’ range (0–3; n = 15).
Relationships With Insight
Bivariate correlation analyses revealed that all indepen-
dent factors significantly correlated with insight (neuro-
cognition: r = .249; P < .001; social cognition: r = .248,
P < .001; and clinical symptoms: r =.290, P < .001). In
addition, neurocognition was significantly correlated
with social cognition (r = .454,P< .001), and both neuro-
cognition and social cognition were inversely correlated
with clinical symptoms (r = .341, P < .001; r = .228,
P < .001). Results of the multiple regression analyses are
displayed in table 2. Neurocognition significantly pre-
dicted insight scores. Social cognition, as an additional
predictor variable, significantly increased the explained
variance (R2change = .020; Pchange = .018). The contribu-
tion of both neurocognition and social cognition was
32
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significant. Finally, clinical symptoms showed a signifi-
cant additional increase in the explained variance.
More specifically, clinical symptoms explained insight
significantly, while the explained variance of neurocogni-
tion was nonsignificant.
The next step was to determine whether the phase of
illness moderated the effect of the independent factors
on insight. When scores of the groups ROP and MECP
were compared, these did not differ with respect to in-
sight (P = .228), neurocognition (P = .308), social cog-
nition (P = .655) nor clinical symptoms (P = .105).
However, when the interaction term neurocognition
was added to a regression model containing neurocog-
nition and the covariates (age, gender, and phase of ill-
ness), the interaction term was significant (b = .549, P =
.037). The same moderating effect of the phase of ill-
ness was found in regression analyses that included so-
cial cognition (b = .483, P = .052) and clinical
symptoms (b =.582, P = .025). These results indicated
that separate analyses for ROP and MECP groups
were justified.
Therefore, final regression analyses were performed sep-
arately for ROP patients and MECP patients. In ROP
patients, neither the neurocognition nor the additional ef-
fect of social cognition (R2change < .002; Pchange = .763)
showed a significant effect. In addition, when clinical
symptoms were also investigated, the explained variance
was again nonsignificant. In MECP patients, it was dem-
onstrated that neurocognition did significantly explain
insight. When social cognition was added to the equation,
the explained variance increased significantly (R2change =
.033; Pchange = .005). Both neurocognition and social cog-
nition significantly explained insight in MECP patients.
With the addition of the variable clinical symptoms to
the above-mentioned equation, the explained variance
increased once again significantly. Clinical symptoms
explained insight significantly, as did neurocognition
and social cognition. In total, the predictors explained
insight for 20%.
Discussion
The current study investigated the relation of insight in
psychosis with neurocognition, social cognition, and clin-
ical symptoms. Results can be summarized as follows:
When investigated separately, neurocognition, social
cognition, and symptom dimensions were all associated
with insight. Phase of illness was found to moderate
the relation between insight and the studied predictors.
In patients with MECP, both social cognition and clinical
symptoms had additional effects and explained insight,
along with neurocognition. In patients with ROP, none
of the factors were found to be associated with insight.
To our best knowledge, this is the first study that has
investigated the unique contribution of neurocognition,
social cognition, and clinical symptoms in relation to in-
sight in psychosis. To demonstrate this, not only the pre-
dictive value of each factor within 1 model was
investigated but also the ‘‘additional’’ predictive value
of the factor. In addition, most of the studies to date
have focused on subfunctions of neurocognition (eg,
working memory) or social cognition (eg, mentalizing)
in relation to insight. The current study used composite
measures for each factor. This implies that multiple tests
have been used to measure the construct, which may rep-
resent a more reliable estimate. Furthermore, the analysis
is more parsimonious because there is no large number of
measures that compromises degrees of freedom.
Table 2. Relationships With Insight for Patients Overall, Patients With ROP and Patients With Multiple Episode Psychosis (MECP)
Patient Group/Model df
Insight Composite Measure
bNeurocognition bSocial Cognition bClinical Symptoms P F R R




Neurocognition 4,262 .250b — — <.001 5.540 .279 .078 — — —
Social cognition 5,261 .177b .159a — <.001 5.642 .312 .098 .018 5.655 .020
Clinical symptoms 6,260 .108 .140a .225b <.001 7.110 .375 .141 <.001 13.141 .043
ROP patients
Neurocognition 3,53 .011 — — .942 .129 .085 .007 — — —
Social cognition 4,52 .019 .051 — .975 .118 .095 .009 .763 .092 .002
Clinical symptoms 5,51 .038 .057 .059 .986 .127 .111 .012 .684 .168 .003
MECP patients
Neurocognition 3,206 .315b — — <.001 8.621 .334 .112 — — —
Social cognition 4,205 .229b .203b — <.001 8.671 .380 .145 .005 7.950 .033
Clinical symptoms 5,204 .148a .169a .258b <.001 10.216 .447 .200 <.001 14.165 .056
Note: b = standardized beta coefficient, Pchange, Fchange, and Rchange refer to the statistical significance of the model as compared with its
preceding model. Included covariates are gender, age, and phase of illness.
aCorrelation significant at the 0.05 level.
bCorrelation significant at the 0.01 level.
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Although this approach may lead to a certain loss of the
fine-grained interpretation of cognitive subfunctions
indexed by individual tests, the results show that each
of the cognitive outcome variables is related to insight
when analyses were restricted to the MECP population
(see supplementary table S1). In fact, the association of
neurocognition with insight within this group (r = .312,
P < .001) is even higher as compared with the results
of a meta-analysis of the previously published literature,5
in which mean weighted effect sizes were reported
ranging from r = .14 to .28.
Social cognition, highly correlating with neurocogni-
tion, explained additional variance on insight. Social cog-
nition has only been investigated in a few studies in
relationship to awareness of illness in psychoses.11,12,43
Our results support previous findings of a significant as-
sociation. For example, Lysaker et al42 found that schizo-
phrenia patients with ‘‘superficial’’ insight not only had
poorer executive function but also poorer emotion recog-
nition ability and capacity for social relationships than
a patient group with ‘‘full awareness.’’ With regard to
mentalizing, Langdon and Ward43 reported an associa-
tion between deficient Theory of Mind performance
(measured with tasks of picture sequencing and joke ap-
preciation) and poor insight. Our findings go beyond
such previous studies because we show that the concept
of social cognition explains ‘‘additional’’ variance when
added to a regression model that already contains a wide
range of neurocognitive variables. Similar results have
been found in studies that investigated the predictive
value of these concepts on distinct functional outcomes,
such as social behavior,44 vocational outcome,45 and in-
terpersonal skills.46 The finding that social cognition
uniquely contributes to insight is supported by theories
that imply a role for deficient mentalizing in reduced in-
sight in one’s illness.12,43,47 That there is a general diffi-
culty in adopting other mental perspectives, ie, with
‘‘seeing the world as others do’’, may contribute to defi-
cient awareness of illness over and above general cogni-
tive problems and next to clinical symptoms. A limitation
of the current study was that a third described social cog-
nitive domain, namely attributional style, was not in-
cluded. In addition, it is possible that the additional
explained variance of social cognition represents a general
capacity to think about thinking, rather than a specific
ability to infer other people’s mental state. This general
capacity has been referred to as ‘‘metacognition,’’ which
also includes the knowledge of one’s own mental
state.48,49 Indeed, a study on metacognitive decisions
in a test of mental flexibility (the Wisconsin Card Sorting
Test) found this to be significantly correlated with insight
in psychosis.50
In ROP patients, neither neurocognition nor social
cognition and clinical symptoms were significantly re-
lated to insight, although their mean scores were not dis-
similar from those with MECP. This is in contrast with
a study by Keshavan et al6, which did find a linear trend
of a composite measure of neurocognition with PANSS
G12 score in ROP patients. An explanation for this dis-
crepancy may be that the correlation between the meas-
ures of insight was modest in the current population
(r = .257, P = .032). Tranulis et al24 have suggested
that, in patients with ROP, specific factors may contrib-
ute to the measurement of insight. Particularly, recent-
onset patients find themselves in a relatively unstable
and evolving period. They may be aware of their distress
but not yet attribute it to a mental disorder. In addition,
different perspectives between the patient who has re-
cently become ill and the interviewer may be responsible
for discrepant findings. A recent study by Parellada et al51
investigated insight in patients with ROP longitudinally
using interview-based measures. The authors suggested
that, during the acute phase, severity of clinical symptoms
might overrule the relationship of ‘‘trait’’-related features
with insight, which in turn becomes more apparent after
symptom stabilization. Viewing the supplementary table
S1, it cannot be ruled out that clinical symptoms are re-
lated to insight in ROP. Thereby, the current study results
are partly in agreement with those of Parelleda et al. Fu-
ture GROUP studies should be able to confirm this using
longitudinal data of the ROP patients.
In line with previous findings, the current study
showed medium relationships between the insight meas-
ures and a relation of its composite score with important
outcome variables such as GAF-scores and number
of hospitalizations.52 Scores on the PANSS and BIS
reflected good insight in 43% of our sample. Although
1 influential study showed that poor insight affected
up to 81% of patients with schizophrenia,53 the numbers
in the present study are consistent with comparable stud-
ies that were published over the last decades.27,54,55 In-
deed, 1 of the largest studies to date that included
a comprehensive assessment of 412 patients found that
41% of schizophrenia patients were aware that they suf-
fered from a mental disorder.56 Treatment factors, such
as the widespread use of psychoeducation in the Nether-
lands, might contribute to the relatively high number of
unimpaired patients in our sample. Alternatively, our
brief measures of insight might have overseen some
insight problems. The use of more comprehensive
interview-based measures such as the Schedule of Assess-
ment of Insight-Expanded version57 and the Scale to As-
sess Unawareness of Mental Disorder58 could yield
a higher sensitivity in that regard. Utilization of such
scales may also allow for a deeper and more comprehen-
sive exploration of the several domains of insight de-
scribed in the ‘‘Introduction’’ section. In addition, it
has recently been suggested that insight should be studied
not only as a belief that leads to treatment adherence, or
the possession of specific knowledge, but also as a facet of
a larger understanding of an individual life, also referred
to as an inextricable part of a personal narrative.42,59
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Another drawback of the current study was the use of
the PANSS for both the independent measure (clinical
symptoms) and the dependent measure (insight, in
part). This may well explain the decrease in explained var-
iance of neurocognition and social cognition when the
contribution clinical symptoms were taken into account
as well. Finally, correlation does not imply causation.
Whereas neurocognitive and social cognitive abilities
may partly underlie the patients’ level of insight, the di-
rection of the effect is less straightforward for clinical
symptoms, such as delusions and hallucinations. For in-
stance, a deluded person without insight in his/her psy-
chotic beliefs may receive higher positive symptom
ratings as compared with a similar person with insight.
Thus, it may not be that stronger symptoms cause
poor insight but that poor insight results in higher symp-
tom ratings.
In conclusion, the results of the current study indicate
that insight in psychosis is associated with multiple fac-
tors and that a distinction between patients in different
phases of their illness may lead to a better understanding
of this concept. Lack of insight in MECP patients may
require not only traditional cognitive aspects (eg, learn-
ing, attending, information processing, remembering)
but also successful perception and interpretation of so-
cial-emotional information. In this, the former may be
necessary to understand the world around us as an indi-
vidual, whereas the latter may be more important to un-
derstand others and oneself; it should be noted that the
border between these concepts is, in reality, more diffuse.
In addition to neurocognition and social cognition, a cer-
tain presence of behavior and emotion and absence of de-
viant perceptions (clinical symptoms) may be
requirements for full insight. It should be noted that
the nature of insight is paradoxical. Patients with full in-
sight have been found to experience more depressive
symptoms and hopelessness,60 and the stigma associated
with having a schizophrenia diagnosis has been suggested
to be a moderating factor.61 However, increasing insight
through treatment does not lead to lasting increases in
depression. Indeed, improved insight has been shown
to be associated with decreased suicidality.62 Indeed,
interventions with positive effects on neuropsychological
aspects, clinical symptoms as well as well-being and func-
tional outcome63 may hypothetically increase insight as
a by-product while preventing the occurrence of negative
effects on depressive symptoms.60 Such interventions
should also address stigma sensitivity and may benefit
from using a broader concept of insight, which incorpo-
rates the personal narrative. How to increase insight in
ROP needs further investigation.
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